Matthew B. Harms, MD
Associate professor of neurology, Columbia University; Medical consultant and care center director, Muscular Dystrophy Association
Articles
Steps in Translating Genetic Discoveries Into Effective Treatments for ALS: Matthew B. Harms, MD
February 24th 2025The associate professor of neurology at Columbia University provided commentary on the rapid advancements in translating genetic research into ALS treatments and the challenges that remain. [WATCH TIME: 5 minutes]
Advancing Therapeutic Knowledge of Genetic Influence in ALS: Matthew B. Harms, MD
February 19th 2025The associate professor of neurology at Columbia University gave clinical insight on what neurologists and other neuromuscular specialists can expect from the ALS/frontotemporal dementia track at this year’s MDA Clinical & Scientific Conference. [WATCH TIME: 3 minutes]
Highlighting Genetic Discoveries and Therapeutic Developments in ALS: Matthew B. Harms, MD
February 21st 2024The associate professor of neurology at Columbia University talked about a track session that he will be chairing at the upcoming MDA conference on amyotrophic lateral sclerosis genetic research. [WATCH TIME: 5 minutes]
The Development of New Gene Therapies to Address Unmet Needs in ALS: Matthew B. Harms, MD
April 7th 2023The associate professor of neurology at Columbia University spoke at the 2023 MDA conference about the unmet needs of patients with ALS and the potential of new gene therapies. [WATCH TIME: 5 minutes]
ALS Advances and Hot Topics for MDA 2023: Matthew B. Harms, MD
March 9th 2023The associate professor of neurology at Columbia University and medical consultant and care center director for MDA offered his insight into the latest progress in ALS treatment and some of what will be discussed at the upcoming MDA Clinical & Scientific Conference.
The Role of Genetics and Database Variety for ALS Research: Matthew B. Harms, MD
May 13th 2022The associate professor of neurology at Columbia University discussed the role of genetics in ALS and how it compares to other neurodegenerative disorders, as well as why having a variety of large databases will prove positive for the field. [WATCH TIME: 4 minutes]
Laying the Foundation in ALS Research: Matthew B. Harms, MD
May 12th 2022The associate professor of neurology at Columbia University spoke to the recent progress made in ALS research and how the neuromuscular field has pushed the envelope to improve care and develop a cure for the disease. [WATCH TIME: 4 minutes]
Patient Conversations About Clinical Development in ALS: Matthew B. Harms, MD
May 10th 2021The associate professor of neurology at Columbia University and medical consultant and care center director at the Muscular Dystrophy Association spoke to the importance of staying up on the latest developments in ALS and keeping patients in the loop on that information.
The Impact of Big Data on ALS Care: Matthew B. Harms, MD
May 9th 2021The associate professor of neurology at Columbia University and medical consultant and care center director at the Muscular Dystrophy Association discussed the use of larger datasets to improve prognostication and clinical trials in ALS.
The Importance of ALS Awareness Month: Matthew B. Harms, MD
May 6th 2021The associate professor of neurology at Columbia University and medical consultant and care center director, Muscular Dystrophy Association, discusses the impact that the Ice Bucket Challenge and ALS Awareness Month have had on the ALS treatment landscape.
